Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 521

1.

Subcutaneous belimumab in the treatment of systemic lupus erythematosus.

Elalouf O, Keeling SO, Touma Z.

Immunotherapy. 2018 Aug 14. doi: 10.2217/imt-2018-0061. [Epub ahead of print]

PMID:
30105936
2.

Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America.

Ferreira JCOA, Trindade VC, Espada G, Morel Z, Bonfá E, Magalhães CS, Silva CA.

Clin Rheumatol. 2018 Aug 9. doi: 10.1007/s10067-018-4254-4. [Epub ahead of print]

PMID:
30094748
3.

The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus.

Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Möller S, Welin Henriksson E, Voss A, Gunnarsson I.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23718. [Epub ahead of print]

PMID:
30055091
4.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, Da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, Alarcón GS; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR).

Ann Rheum Dis. 2018 Jul 25. pii: annrheumdis-2018-213512. doi: 10.1136/annrheumdis-2018-213512. [Epub ahead of print]

5.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Hruskova Z, Tesar V.

Expert Opin Biol Ther. 2018 Jul 31:1-8. doi: 10.1080/14712598.2018.1504918. [Epub ahead of print]

PMID:
30040494
6.

Belimumab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

7.

Immunotherapy of systemic sclerosis.

Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI.

Hum Vaccin Immunother. 2018 Jul 9:1-9. doi: 10.1080/21645515.2018.1491508. [Epub ahead of print]

PMID:
29985736
8.

Smoking reduces the efficacy of belimumab in mucocutaneous lupus.

Parodis I, Gomez A, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I.

Expert Opin Biol Ther. 2018 Aug;18(8):911-920. doi: 10.1080/14712598.2018.1494719. Epub 2018 Jul 9.

PMID:
29958508
9.

Emerging Targets for the Treatment of Lupus Erythematosus: There is No Royal Road to Treating Lupus.

Yasuda S.

Mod Rheumatol. 2018 Jun 27:1-25. doi: 10.1080/14397595.2018.1493909. [Epub ahead of print]

PMID:
29947283
10.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR.

Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14.

PMID:
29910042
11.

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials.

Felten R, Dervovic E, Chasset F, Gottenberg JE, Sibilia J, Scher F, Arnaud L.

Autoimmun Rev. 2018 Aug;17(8):781-790. doi: 10.1016/j.autrev.2018.02.011. Epub 2018 Jun 6. Review.

PMID:
29885544
12.

[Thirteen reasons why B cell may not be the best therapeutic target in systemic lupus erythematosus].

Chiche LY.

Rev Med Interne. 2018 May 28. pii: S0248-8663(18)30574-5. doi: 10.1016/j.revmed.2018.05.005. [Epub ahead of print] French. No abstract available.

PMID:
29853262
13.
14.

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.

Lupus. 2018 Aug;27(9):1489-1498. doi: 10.1177/0961203318777634. Epub 2018 May 28.

15.

[Systemic Lupus Erythematosus (SLE) - New Classification Criteria].

Aringer M, Dörner T.

Dtsch Med Wochenschr. 2018 Jun;143(11):811-814. doi: 10.1055/a-0542-3409. Epub 2018 May 28. German.

PMID:
29807382
16.

Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.

Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D.

Mod Rheumatol. 2018 Jul 20:1-9. doi: 10.1080/14397595.2018.1480915. [Epub ahead of print]

PMID:
29792370
17.

Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab.

Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D.

Ann Rheum Dis. 2018 May 18. pii: annrheumdis-2018-213496. doi: 10.1136/annrheumdis-2018-213496. [Epub ahead of print] No abstract available.

PMID:
29776976
18.

Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation.

Hulbert AL, Pavlisko EN, Palmer SM.

Curr Opin Organ Transplant. 2018 Jun;23(3):308-315. doi: 10.1097/MOT.0000000000000537.

PMID:
29742565
19.

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Trentin F, Gatto M, Zen M, Larosa M, Nalotto L, Saccon F, Zanatta E, Iaccarino L, Doria A.

Clin Rev Allergy Immunol. 2018 Apr 16. doi: 10.1007/s12016-018-8682-3. [Epub ahead of print]

PMID:
29736902
20.

An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.

Ramachandran S, Parks D, Kurtinecz M, Roth DA, Alfonso-Cristancho R.

J Comp Eff Res. 2018 Jun;7(6):581-593. doi: 10.2217/cer-2017-0085. Epub 2018 Apr 25.

Supplemental Content

Loading ...
Support Center